Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT02184533, this PHASE1 trial focuses on Adenocarcinoma of the Prostate and Hormone-resistant Prostate Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Apr 2019 — Mar 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .